RETREAT评分预测肝移植后HCC复发的前瞻性多中心验证
研究前瞻性纳入8中心2018至2022年1166例因HCC行肝移植患者,验证RETREAT评分预测移植后HCC复发的准确性。中位随访2.2年,78例(6.7%)复发;RETREAT评分0、3、5+者3年无复发生存率分别为99.4%、84.1%、55.6%。RETREAT评分一致性指数0.81(95%CI 0.77-0.85),在多指标上优于MORAL和RELAPSE评分。
要点
- RETREAT评分0、3、5+者移植后3年无复发生存率分别为99.4%、84.1%、55.6%。
- RETREAT评分一致性指数0.81(95%CI 0.77-0.85),优于MORAL和RELAPSE评分。
- RETREAT评分可分层移植后总生存和复发后生存。
核心结论
- RETREAT评分对预测肝移植后HCC复发保持高准确性,进一步支持RETREAT指导的移植后HCC监测和诊疗。
研究设计与样本
- 前瞻性多中心队列研究,纳入8个中心2018至2022年因HCC行肝移植的患者1166例。
- 主要结局为移植后无复发生存,次要结局包括移植后生存和复发后生存。
- 采用一致性指数、赤池信息准则、积分Brier评分和校准比较RETREAT与其他风险评分。
主要发现
- 中位随访2.2年(IQR 1.2-3.2),78例(6.7%)发生移植后HCC复发。
- 复发患者RETREAT评分中位数4分(IQR 3-5),未复发患者1分(IQR 1-2)。
- RETREAT评分0、3、5+者移植后3年无复发生存率分别为99.4%、84.1%、55.6%。
- RETREAT评分一致性指数0.81(95%CI 0.77-0.85),在多个指标上优于MORAL和RELAPSE评分。
临床怎么用
- 原文未据此给出推荐,仅指出结果进一步支持RETREAT指导的移植后HCC监测和诊疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The RETREAT(Risk Estimation of Tumor REcurrence After Transplant) score is a simple risk stratification tool for postliver transplantation (LT) HCC recurrence that has been validated in retrospective cohort studies. A prospective, multicenter study is needed to further demonstrate accuracy especially given the evolving clinical demographics and HCC transplant practice. Our aim is to validate and compare the RETREAT score to other post-LT HCC recurrence risk scores in a contemporary, prospective cohort of patients. APPROACH AND RESULTS: We prospectively enrolled patients with HCC who underwent LT from 8 centers between 2018 and 2022. The primary outcome was post-LT recurrence-free survival. Secondary outcomes included post-LT and post-recurrence survival. Model performance, determined using the concordance index, Akaike information criterion, integrated Brier score, and calibration, was compared to that of other established risk scores.We included 1166 patients with HCC who underwent LT, of which 78 (6.7%) had post-LT HCC recurrence after a median follow-up time of 2.2 years (IQR 1.2-3.2). The median RETREAT score was 4 (IQR 3-5) in patients with post-LT HCC recurrence and 1 (IQR 1 - 2) in patients without. Those with a RETREAT score of 0, 3, and 5+ had a 99.4%, 84.1%, and 55.6% recurrence-free survival, respectively, at 3 years post-LT. The RETREAT score was also able to stratify post-LT overall and postrecurrence survival. The RETREAT score's concordance index was 0.81 (95% CI: 0.77-0.85) and outperformed the MORAL and RELAPSE scores across multiple metrics. CONCLUSIONS: The RETREAT score retains high accuracy for predicting post-LT HCC recurrence, further supporting RETREAT-guided post-LT HCC surveillance and care.
引用
- Li PJ, Tabrizian P, Daher D, et al. A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction. Hepatology. 2025. PMID: 40067686. doi:10.1097/HEP.0000000000001297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。